The study, Medicaid Coverage and Prior Authorization for Antiobesity Glucagon-Like Peptide-1 Receptor Agonists: A Cross- Sectional Study of State Policies, was published on November 21, 2025 in the Journal of General Internal Medicine
While GLP-1 microdosing is generating significant interest, it's important to understand what it is, what researchers know so far, and where questions still remain
These medications may provide major benefits for diabetes control, weight loss, heart health, and kidney health
The adverse effect profiles of these compounds also differ
What makes Sofwave particularly relevant for GLP-1 patients is its ability to address skin laxity across multiple areas: the face, neck, jawline, arms, abdomen, and thighs
Es comn recuperar parte del peso perdido si se suspende sin un plan de mantenimiento (alimentacin, actividad fsica) acompaado por un especialista